EA005236B1 - Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты) - Google Patents

Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты) Download PDF

Info

Publication number
EA005236B1
EA005236B1 EA200100385A EA200100385A EA005236B1 EA 005236 B1 EA005236 B1 EA 005236B1 EA 200100385 A EA200100385 A EA 200100385A EA 200100385 A EA200100385 A EA 200100385A EA 005236 B1 EA005236 B1 EA 005236B1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
factor
antibody
composition
factor viii
Prior art date
Application number
EA200100385A
Other languages
English (en)
Russian (ru)
Other versions
EA200100385A1 (ru
Inventor
Гэри С. Грэй
Джиахуа Киан
Мэри Коллинс
Леон У. Хойэр
Original Assignee
ДЖИНЕТИКС ИНСТИТЬЮТ, эЛэЛСи
Эмерикэн Ред Кросс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЖИНЕТИКС ИНСТИТЬЮТ, эЛэЛСи, Эмерикэн Ред Кросс filed Critical ДЖИНЕТИКС ИНСТИТЬЮТ, эЛэЛСи
Publication of EA200100385A1 publication Critical patent/EA200100385A1/ru
Publication of EA005236B1 publication Critical patent/EA005236B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA200100385A 1998-09-21 1999-09-21 Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты) EA005236B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (2)

Publication Number Publication Date
EA200100385A1 EA200100385A1 (ru) 2001-10-22
EA005236B1 true EA005236B1 (ru) 2004-12-30

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100385A EA005236B1 (ru) 1998-09-21 1999-09-21 Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)

Country Status (21)

Country Link
EP (1) EP1115423A1 (hu)
JP (1) JP2002526455A (hu)
KR (1) KR20010085830A (hu)
CN (1) CN1331602A (hu)
AU (1) AU761206B2 (hu)
BR (1) BR9913991A (hu)
CA (1) CA2343916A1 (hu)
CZ (1) CZ20011021A3 (hu)
EA (1) EA005236B1 (hu)
HK (1) HK1039059A1 (hu)
HU (1) HUP0103960A3 (hu)
IL (1) IL142069A0 (hu)
LT (1) LT4920B (hu)
LV (1) LV12768B (hu)
MX (1) MXPA01002898A (hu)
NO (1) NO20011412L (hu)
NZ (1) NZ511034A (hu)
PL (1) PL346796A1 (hu)
SI (1) SI20626A (hu)
WO (1) WO2000016801A1 (hu)
ZA (1) ZA200103156B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO2001089564A2 (en) * 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
JP2007516509A (ja) * 2003-06-10 2007-06-21 スミスズ ディテクション インコーポレイティド センサ装置
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3722375B2 (ja) 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0776217A1 (en) * 1994-08-19 1997-06-04 Novo Nordisk A/S A method of treating a patient with a biologically active compound
EP0804076A4 (en) * 1994-10-19 1998-10-21 Genetic Therapy Inc GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l
BR9810755A (pt) * 1997-06-20 2000-08-15 Biogen Inc Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica
US8151477B2 (en) 2009-11-06 2012-04-10 Hexagon Metrology Ab CMM with modular functionality

Also Published As

Publication number Publication date
WO2000016801A1 (en) 2000-03-30
EP1115423A1 (en) 2001-07-18
CN1331602A (zh) 2002-01-16
HUP0103960A3 (en) 2003-09-29
LV12768A (en) 2001-12-20
EA200100385A1 (ru) 2001-10-22
NZ511034A (en) 2004-03-26
LT4920B (lt) 2002-06-25
HK1039059A1 (zh) 2002-04-12
AU761206B2 (en) 2003-05-29
WO2000016801A9 (en) 2000-10-26
BR9913991A (pt) 2001-07-03
LT2001045A (en) 2002-01-25
JP2002526455A (ja) 2002-08-20
PL346796A1 (en) 2002-02-25
ZA200103156B (en) 2002-07-18
KR20010085830A (ko) 2001-09-07
NO20011412D0 (no) 2001-03-20
SI20626A (sl) 2002-02-28
HUP0103960A2 (hu) 2002-02-28
MXPA01002898A (es) 2002-06-04
IL142069A0 (en) 2002-03-10
AU6057899A (en) 2000-04-10
LV12768B (lv) 2002-06-20
CZ20011021A3 (cs) 2001-10-17
CA2343916A1 (en) 2000-03-30
NO20011412L (no) 2001-05-16

Similar Documents

Publication Publication Date Title
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
Shenoy-Scaria et al. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1.
KR100257466B1 (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
Benjamin et al. Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination
Skok et al. Alpha subunit composition of nicotinic acetylcholine receptors in the rat autonomic ganglia neurons as determined with subunit-specific anti-α (181–192) peptide antibodies
Wang et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis
JP2003520828A (ja) Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
Qian et al. Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer
EP1755660A2 (en) Method for enhancing or inhibiting insulin-like growth factor-i
EA021131B1 (ru) Антитела и способы их получения
Clarke Mechanisms of adverse drug reactions to biologics
US20050163780A1 (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen
BG107214A (bg) Пептид, модулиращ тромбопоетиновия рецептор
US20210355231A1 (en) Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
AU2004240180B2 (en) Methods of prolonged suppression of humoral immunity
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
EA005236B1 (ru) Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)
US20030161827A1 (en) Therapies that improve graft survival
US20010055593A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
JPH07501524A (ja) ｕＰＡ−Ｒの検出・分離方法及びｕＰＡのｕＰＡ−Ｒへの結合阻止方法
Greenwood et al. Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice
WO1997017360A2 (en) Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
WO1998016548A1 (en) Thrombin receptor peptides and uses thereof
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
AU2005295918A1 (en) Methods and materials for the inhibition of transplant rejection

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU